Cirrhosis Regression Based On Both Enhanced Liver Fibrosis (Elf) And Fibrotest After Direct-Acting Hepatitis C Therapeutics Corresponded To A Lower Incidence Rate Of Hepatocellular Carcinoma (Hcc) Below The Cost-Effective Threshold For Surveillance